http://globenewswire.com/news-release/2014/09/29/669185/10100382/en/Catalyst-Pharmaceuticals-Announces-Positive-Top-Line-Phase-3-Data-From-Pivotal-Firdapse-Clinical-Trial-in-Patients-With-Lambert-Eaton-Myasthenic-Syndrome-LEMS.html

Comments

Popular posts from this blog

$$$$ grant funding $$$$

PNSEURONET international group of neurologists interested in the field of paraneoplastic syndromes.....